Effects of Short-Course Zidovudine on the Selection of Nevirapine-Resistant HIV-1 in Women Taking Single-Dose Nevirapine | Zendy

Mark A. Micek | Zendy; Ana Judith Blanco | Zendy; Jacquelyn Carlsson | Zendy; Ingrid A. Beck | Zendy; Sandra Dross | Zendy; Laurinda Matunha | Zendy; Kristy Seidel | Zendy; Pablo Montoya | Zendy; Soren Gantt | Zendy; Eduardo Matediana | Zendy; Lilia Jamisse | Zendy; Stephen Gloyd | Zendy; Lisa M. Frenkel | Zendy

Open Access

Effects of Short-Course Zidovudine on the Selection of Nevirapine-Resistant HIV-1 in Women Taking Single-Dose Nevirapine

Author(s) -

Mark A. Micek,

Ana Judith Blanco,

Jacquelyn Carlsson,

Ingrid A. Beck,

Sandra Dross,

Laurinda Matunha,

Kristy Seidel,

Pablo Montoya,

Soren Gantt,

Eduardo Matediana,

Lilia Jamisse,

Stephen Gloyd,

Lisa M. Frenkel

Publication year - 2012

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jis282

Subject(s) - nevirapine , zidovudine , virology , human immunodeficiency virus (hiv) , medicine , viral disease , antiretroviral therapy , viral load

Single-dose nevirapine (sdNVP) given to prevent mother-to-child-transmission of HIV-1 selects NVP-resistance. Short-course zidovudine (ZDV) was hypothesized to lower rates of NVP-resistance. HIV-1 infected pregnant women administered sdNVP with or without short-course ZDV were assessed for HIV-1 mutations (K103N, Y181C, G190A, and V106M) prior to delivery and postpartum. Postpartum NVP-resistance was lower among 31 taking ZDV+sdNVP compared to 33 taking only sdNVP (35.5% vs. 72.7%; χ2 P = .003). NVP mutants decayed to <2% in 24/35 (68.6%) at a median 6 months postpartum, with no differences based on ZDV use (logrank P = .99). Short-course ZDV was associated with reduced NVP-resistance mutations among women taking sdNVP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research